LIN vs UTHR · P/E 34, rev $33.99B vs P/E 20, rev $2.88B
Linde plc Ordinary Shares (LIN) versus United Therapeutics Corporation (UTHR) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
United Therapeutics Corporation (UTHR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported UTHR revenue for 2024-12-31 was $2.88B. Net income was $1.20B. Revenue was up 23.6% from 2023-12-31 to 2024-12-31. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
Not investment advice. Open the LIN and UTHR stock pages for the full models.
Not investment advice.